Price Alert

Tarsus Pharmaceuticals In... (TARS)

NASDAQ: TARS · Real-Time Price · USD

57.43

-0.29 (-0.50%)

At close: Sep 04, 2025, 3:59 PM

58.00

0.99%

Pre-market: Sep 05, 2025, 06:04 AM EDT

-0.50% (1D)

Bid	54.5
Market Cap	2.42B
Revenue (ttm)	295.52M
Net Income (ttm)	-91.99M
EPS (ttm)	-2.29
PE Ratio (ttm)	-25.08
Forward PE	59.51
Analyst	Buy

Ask	60
Volume	519,287
Avg. Volume (20D)	634,895
Open	57.64
Previous Close	57.72
Day's Range	56.66 - 58.45
52-Week Range	27.18 - 59.76
Beta	0.79

About TARS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TARS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TARS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Tarsus Pharmaceuticals Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-5.84%

Tarsus Pharmaceuticals shares are trading lower fo... Unlock content with Pro Subscription

6 months ago

-9.33%

Shares of Tarsus Pharmaceuticals are trading lower. The company reported Q4 financial results.

News

1 week ago · marketbeat.com

3 Biotech Catalysts Present Major Opportunity

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a ...

2 weeks ago · benzinga.com

Top 2 Health Care Stocks That May Fall Off A Cliff In August

As of Aug. 20, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

4 weeks ago · seekingalpha.com

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Aziz Mottiwala - Chief Commercial Officer Bobak R. Azamian - Co-Founder, Pre...

1 month ago · zacks.com

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.88 per share a year ago.